Search research articles
Contact Us
Filters
Showing results (171-180 of 225) with videos related to
Page
of 23
Sort By:
Blood Advances
|
January 1, 2024
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
Inhye E Ahn, Danielle M Brander, Yue Ren, et al.
The Lancet. Haematology
|
June 19, 2019
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial
Matthew S Davids, Danielle M Brander, Haesook T Kim, et al.
Blood
|
October 6, 2018
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W Flinn, Peter Hillmen, Marco Montillo, et al.
Blood Advances
|
October 26, 2022
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
Aishath Naeem, Filippo Utro, Qing Wang, et al.
American Journal of Hematology
|
July 1, 2024
Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole cytogenetic abnormality display a high frequency of RPS15 mutations and have a poor prognosis
Claudia Pérez Carretero, Teresa González, Miguel Quijada Álamo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2017
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S Davids, Andrew W Roberts, John F Seymour, et al.
Science Translational Medicine
|
June 15, 2018
Statins enhance efficacy of venetoclax in blood cancers
J Scott Lee, Andrew Roberts, Dennis Juarez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2021
Venetoclax in Previously Treated Waldenström Macroglobulinemia
Jorge J Castillo, John N Allan, Tanya Siddiqi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2024
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Blood
|
November 10, 2020
miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors
Sonali Sharma, Gabriela Mladonicka Pavlasova, Vaclav Seda, et al.
Page
of 23
Search research articles
Search
Showing results (171-180 of 225) with videos related to
Sort By:
Page
of 23
Blood Advances
|
January 1, 2024
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
Inhye E Ahn, Danielle M Brander, Yue Ren, et al.
The Lancet. Haematology
|
June 19, 2019
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial
Matthew S Davids, Danielle M Brander, Haesook T Kim, et al.
Blood
|
October 6, 2018
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W Flinn, Peter Hillmen, Marco Montillo, et al.
Blood Advances
|
October 26, 2022
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
Aishath Naeem, Filippo Utro, Qing Wang, et al.
American Journal of Hematology
|
July 1, 2024
Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole cytogenetic abnormality display a high frequency of RPS15 mutations and have a poor prognosis
Claudia Pérez Carretero, Teresa González, Miguel Quijada Álamo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 18, 2017
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S Davids, Andrew W Roberts, John F Seymour, et al.
Science Translational Medicine
|
June 15, 2018
Statins enhance efficacy of venetoclax in blood cancers
J Scott Lee, Andrew Roberts, Dennis Juarez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2021
Venetoclax in Previously Treated Waldenström Macroglobulinemia
Jorge J Castillo, John N Allan, Tanya Siddiqi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2024
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Blood
|
November 10, 2020
miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors
Sonali Sharma, Gabriela Mladonicka Pavlasova, Vaclav Seda, et al.
Page
of 23